Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial

scientific article published on 24 August 2017

Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/1078-0432.CCR-17-1597
P8608Fatcat IDrelease_svbkx3uu3jhaxkltdfmwwprc74
P932PMC publication ID5796858
P698PubMed publication ID28839110

P50authorJoseph D. KhouryQ87653316
P2093author name stringStanley R Hamilton
L Jeffrey Medeiros
Neda Kalhor
Russell Broaddus
Meera Hameed
Victor G Prieto
Wei-Lien Wang
P2860cites workA landscape of driver mutations in melanomaQ24603357
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancerQ24614511
RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable databaseQ24813953
Molecular mechanisms underlying RB protein functionQ27003956
Targeting the RB-E2F pathway in breast cancerQ28069626
PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyQ28262647
Proposals for the classification of the myelodysplastic syndromesQ28275931
Targeting PI3K signalling in cancer: opportunities, challenges and limitationsQ29617685
Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group StudyQ30361978
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancerQ33586020
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateQ33862786
Palbociclib: an evidence-based review of its potential in the treatment of breast cancerQ34027724
The STARD statement for reporting studies of diagnostic accuracy: explanation and elaborationQ34167832
Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducibleQ34574472
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes.Q34786717
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpointsQ34943776
Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.Q35063442
Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testingQ35740291
Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencingQ35926060
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone developmentQ36193517
???Q26829177
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.Q36271327
Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomasQ37038863
Next-generation companion diagnostics: promises, challenges, and solutionsQ37190679
Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice GuidelinesQ37659105
Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasmsQ38065071
Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality CenterQ38197280
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials NetworkQ38214265
Wilms tumor 1 (WT1) protein: Diagnostic utility in pediatric tumorsQ38424214
Principles of Analytic Validation of Clinical Immunohistochemistry Assays.Q38603134
Treating cancer with selective CDK4/6 inhibitorsQ38794109
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.Q38833458
Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial CarcinomaQ38848447
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.Q39007646
The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade 1/2 follicular lymphomas.Q51020727
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Q51692190
The evolving potential of companion diagnostics.Q53064168
Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.Q53190261
PTEN/MMAC1 mutations in endometrial cancers.Q53439663
High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- miceQ57272679
Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumorsQ57741132
Site and Tumor Type Predicts DNA Mismatch Repair Status in Cutaneous Sebaceous NeoplasiaQ57741270
Recommendations for Improved Standardization of ImmunohistochemistryQ58376162
Genetic Interactions in Cancer Progression and TreatmentQ63383811
NCI-MATCH pairs tumor mutations with matching drugsQ85852392
Advanced Companion Diagnostics Facilities: Opportunity Favors the Prepared LaboratoryQ86297542
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectimmunohistochemistryQ899285
biomarkerQ864574
P304page(s)521-531
P577publication date2017-08-24
P1433published inClinical Cancer ResearchQ332253
P1476titleValidation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial
P478volume24

Reverse relations

cites work (P2860)
Q90024930Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
Q92381135Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update
Q57100413Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience
Q98733440Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features
Q89163281Molecular diagnostic testing of diffuse gliomas in the real-life setting: A practical approach
Q58594810Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria
Q64905628Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
Q64996202PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm.
Q59330598Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution

Search more.